Alector Reports 2021 First Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/21
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's DiseaseGlobeNewsWire • 01/25/21
Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% UpsideSeeking Alpha • 12/07/20
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/20
Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific ForumsGlobeNewsWire • 10/22/20
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/20
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal DementiaGlobeNewsWire • 07/28/20
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal DementiaGlobeNewsWire • 07/24/20
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International ConferenceGlobeNewsWire • 07/21/20